HRP20080559T3 - 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators - Google Patents
2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulatorsInfo
- Publication number
- HRP20080559T3 HRP20080559T3 HR20080559T HRP20080559T HRP20080559T3 HR P20080559 T3 HRP20080559 T3 HR P20080559T3 HR 20080559 T HR20080559 T HR 20080559T HR P20080559 T HRP20080559 T HR P20080559T HR P20080559 T3 HRP20080559 T3 HR P20080559T3
- Authority
- HR
- Croatia
- Prior art keywords
- 4alkyl
- phenyl
- alkyl
- group
- carbon
- Prior art date
Links
- GKXZNNBMEDANBL-UHFFFAOYSA-N 2-(quinoxalin-5-ylsulfonylamino)benzamide Chemical class NC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC2=NC=CN=C12 GKXZNNBMEDANBL-UHFFFAOYSA-N 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 10-oxa-4-aza-tricyclo [5.2.1.02,6] dec-4-yl Chemical group 0.000 abstract 3
- 125000005605 benzo group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49407403P | 2003-08-08 | 2003-08-08 | |
| PCT/US2004/025153 WO2005016896A1 (fr) | 2003-08-08 | 2004-08-04 | Composes de 2- (quinoxaline-5-ylsulfonylamino) -benzamide utilises en tant que modulateur du recepteur cck2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080559T3 true HRP20080559T3 (en) | 2009-01-31 |
Family
ID=34193199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080559T HRP20080559T3 (en) | 2003-08-08 | 2008-11-03 | 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7288651B2 (fr) |
| EP (2) | EP1651621B1 (fr) |
| JP (2) | JP4818110B2 (fr) |
| KR (1) | KR20060060007A (fr) |
| CN (2) | CN1863782A (fr) |
| AR (1) | AR045930A1 (fr) |
| AT (2) | ATE353322T1 (fr) |
| AU (2) | AU2004265311A1 (fr) |
| BR (1) | BRPI0413449A (fr) |
| CA (2) | CA2534887A1 (fr) |
| CR (1) | CR8229A (fr) |
| CY (1) | CY1106486T1 (fr) |
| DE (2) | DE602004004663T2 (fr) |
| DK (2) | DK1651622T3 (fr) |
| EA (1) | EA200600203A1 (fr) |
| EC (1) | ECSP066355A (fr) |
| ES (2) | ES2281834T3 (fr) |
| HR (1) | HRP20080559T3 (fr) |
| IL (1) | IL173591A0 (fr) |
| IS (1) | IS8280A (fr) |
| LT (1) | LT5410B (fr) |
| LV (1) | LV13453B (fr) |
| MX (2) | MXPA06001550A (fr) |
| NO (1) | NO20061122L (fr) |
| NZ (1) | NZ545030A (fr) |
| PL (2) | PL1651622T3 (fr) |
| PT (2) | PT1651621E (fr) |
| SG (1) | SG131114A1 (fr) |
| SI (2) | SI1651622T1 (fr) |
| TW (1) | TW200521120A (fr) |
| UA (1) | UA84025C2 (fr) |
| WO (2) | WO2005016897A1 (fr) |
| ZA (1) | ZA200601946B (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004004663T2 (de) * | 2003-08-08 | 2007-11-22 | Janssen Pharmaceutica N.V. | Verfahren zur herstellung von 2- (chinoxalin-5-ylsulfonylamino) -benzamid-verbindungen |
| WO2005085188A2 (fr) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Composes et procedes pour la therapie antitumorale |
| JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
| US7947833B2 (en) * | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| KR20070057252A (ko) | 2004-09-24 | 2007-06-04 | 얀센 파마슈티카 엔.브이. | 설폰아미드 화합물 |
| FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| US8592565B2 (en) * | 2007-01-12 | 2013-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Preparation of azide-modified carbon surfaces for coupling to various species |
| US8247403B2 (en) * | 2007-03-07 | 2012-08-21 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| WO2008124518A1 (fr) * | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Composés de sulfonamide d'oxo-dihydroisoindole comme modulateurs de récepteur cck2 |
| EP2131243B1 (fr) * | 2008-06-02 | 2015-07-01 | ASML Netherlands B.V. | Appareil lithographique et procédé de calibration de position d'un dispositif de support |
| US8354557B2 (en) * | 2008-06-17 | 2013-01-15 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| US20100305093A1 (en) * | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
| WO2011044506A2 (fr) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Composés sulfonés et leurs procédés de fabrication et d'utilisation |
| ES2529233T3 (es) | 2010-07-09 | 2015-02-18 | Convergence Pharmaceuticals Limited | Compuestos tetrazol como bloqueadores de canales de calcio |
| AU2011281037B2 (en) | 2010-07-22 | 2014-11-27 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| CA2825408A1 (fr) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Composes de tetrazole et procedes de preparation et d'utilisation de ceux-ci |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| WO2012154676A1 (fr) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Composés tricycliques partiellement saturés et leurs procédés de fabrication et d'utilisation |
| CA2835195A1 (fr) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Composes de sulfonamide tricycliques et leurs procedes de fabrication et d'utilisation |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| KR20140112566A (ko) | 2012-01-18 | 2014-09-23 | 자프겐 인크. | 삼환식 설폰 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
| MX2014008706A (es) | 2012-01-18 | 2015-03-05 | Zafgen Inc | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. |
| US8815915B2 (en) * | 2012-03-01 | 2014-08-26 | Allergan, Inc. | Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators |
| EP2925737B1 (fr) | 2012-11-05 | 2017-06-14 | Zafgen, Inc. | Composés tricycliques à utiliser dans le traitement et/ou la lutte contre l'obésité |
| AU2013337282A1 (en) | 2012-11-05 | 2015-05-21 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| CA2890343A1 (fr) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Composes tricycliques utiles pour le traitement de troubles hepatiques |
| JP6361168B2 (ja) * | 2013-06-17 | 2018-07-25 | Jsr株式会社 | 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物 |
| CN103524386B (zh) * | 2013-10-24 | 2016-05-18 | 江苏鼎龙科技有限公司 | 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法 |
| EP3071206B1 (fr) | 2013-11-22 | 2021-02-17 | CL Biosciences LLC | Antagonistes du gastrin (par exemple yf476, netazepide) pour le traitement et la prevention de l' osteoporose |
| KR20170016754A (ko) * | 2015-08-04 | 2017-02-14 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN106565509A (zh) * | 2016-11-03 | 2017-04-19 | 江苏鼎龙科技有限公司 | 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法 |
| KR101894091B1 (ko) | 2018-01-23 | 2018-08-31 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN108218806B (zh) * | 2018-04-02 | 2019-03-01 | 上海馨远医药科技有限公司 | 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法 |
| CN111285806B (zh) * | 2018-12-06 | 2022-04-15 | 中国医学科学院药物研究所 | 吡唑类化合物及其制备方法、用途和药物组合物 |
| CN116675684B (zh) * | 2023-08-02 | 2023-11-07 | 上海翰森生物医药科技有限公司 | 含炔基稠环类衍生物拮抗剂、其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200420D0 (en) * | 1992-01-09 | 1992-02-26 | James Black Foundation The Lim | Amino acid derivatives |
| CA2167154A1 (fr) * | 1993-08-10 | 1995-02-16 | Sarkis Barret Kalindjian | Ligands aux recepteurs de cck ou de gastrine |
| US6239131B1 (en) | 1996-12-10 | 2001-05-29 | Zeria Pharmaceutical Co., Ltd. | 1,5 Benzodiazepine derivatives |
| DE10121002A1 (de) | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121003A1 (de) | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10134721A1 (de) * | 2001-07-17 | 2003-02-06 | Bayer Ag | Tetrahydrochinoxaline |
| ITTO20020674A1 (it) * | 2002-07-26 | 2004-01-26 | Rotta Research Lab | Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico |
| US6943170B2 (en) * | 2002-11-14 | 2005-09-13 | Bristol-Myers Squibb Company | N-cycloalkylglycines as HIV protease inhibitors |
| DE602004004663T2 (de) | 2003-08-08 | 2007-11-22 | Janssen Pharmaceutica N.V. | Verfahren zur herstellung von 2- (chinoxalin-5-ylsulfonylamino) -benzamid-verbindungen |
| KR20070057252A (ko) * | 2004-09-24 | 2007-06-04 | 얀센 파마슈티카 엔.브이. | 설폰아미드 화합물 |
-
2004
- 2004-08-04 DE DE602004004663T patent/DE602004004663T2/de not_active Expired - Lifetime
- 2004-08-04 CN CNA200480029094XA patent/CN1863782A/zh active Pending
- 2004-08-04 EP EP04780055A patent/EP1651621B1/fr not_active Expired - Lifetime
- 2004-08-04 JP JP2006523230A patent/JP4818110B2/ja not_active Expired - Fee Related
- 2004-08-04 AU AU2004265311A patent/AU2004265311A1/en not_active Abandoned
- 2004-08-04 EP EP04780056A patent/EP1651622B1/fr not_active Expired - Lifetime
- 2004-08-04 SI SI200430245T patent/SI1651622T1/sl unknown
- 2004-08-04 NZ NZ545030A patent/NZ545030A/en unknown
- 2004-08-04 AT AT04780056T patent/ATE353322T1/de not_active IP Right Cessation
- 2004-08-04 SG SG200701706-4A patent/SG131114A1/en unknown
- 2004-08-04 MX MXPA06001550A patent/MXPA06001550A/es active IP Right Grant
- 2004-08-04 UA UAA200601931A patent/UA84025C2/ru unknown
- 2004-08-04 AU AU2004265312A patent/AU2004265312B2/en not_active Expired - Fee Related
- 2004-08-04 PT PT04780055T patent/PT1651621E/pt unknown
- 2004-08-04 WO PCT/US2004/025154 patent/WO2005016897A1/fr active IP Right Grant
- 2004-08-04 PL PL04780056T patent/PL1651622T3/pl unknown
- 2004-08-04 PT PT04780056T patent/PT1651622E/pt unknown
- 2004-08-04 PL PL04780055T patent/PL1651621T3/pl unknown
- 2004-08-04 WO PCT/US2004/025153 patent/WO2005016896A1/fr active IP Right Grant
- 2004-08-04 DE DE602004015614T patent/DE602004015614D1/de not_active Expired - Lifetime
- 2004-08-04 DK DK04780056T patent/DK1651622T3/da active
- 2004-08-04 US US10/910,983 patent/US7288651B2/en active Active
- 2004-08-04 KR KR1020067002650A patent/KR20060060007A/ko not_active Application Discontinuation
- 2004-08-04 US US10/910,925 patent/US7304051B2/en active Active
- 2004-08-04 ES ES04780056T patent/ES2281834T3/es not_active Expired - Lifetime
- 2004-08-04 MX MXPA06001482A patent/MXPA06001482A/es active IP Right Grant
- 2004-08-04 DK DK04780055T patent/DK1651621T3/da active
- 2004-08-04 CN CNA2004800290901A patent/CN1863781A/zh active Pending
- 2004-08-04 BR BRPI0413449-4A patent/BRPI0413449A/pt not_active IP Right Cessation
- 2004-08-04 JP JP2006523231A patent/JP2007501842A/ja not_active Withdrawn
- 2004-08-04 SI SI200430901T patent/SI1651621T1/sl unknown
- 2004-08-04 EA EA200600203A patent/EA200600203A1/ru unknown
- 2004-08-04 CA CA002534887A patent/CA2534887A1/fr not_active Abandoned
- 2004-08-04 CA CA2534885A patent/CA2534885C/fr not_active Expired - Lifetime
- 2004-08-04 AT AT04780055T patent/ATE403650T1/de not_active IP Right Cessation
- 2004-08-04 ES ES04780055T patent/ES2310294T3/es not_active Expired - Lifetime
- 2004-08-06 AR ARP040102814A patent/AR045930A1/es not_active Application Discontinuation
- 2004-08-06 TW TW093123552A patent/TW200521120A/zh unknown
-
2006
- 2006-01-31 IS IS8280A patent/IS8280A/is unknown
- 2006-02-07 IL IL173591A patent/IL173591A0/en unknown
- 2006-02-08 EC EC2006006355A patent/ECSP066355A/es unknown
- 2006-02-08 CR CR8229A patent/CR8229A/es unknown
- 2006-02-08 LV LVP-06-18A patent/LV13453B/en unknown
- 2006-03-07 LT LT2006017A patent/LT5410B/lt not_active IP Right Cessation
- 2006-03-07 ZA ZA200601946A patent/ZA200601946B/en unknown
- 2006-03-08 NO NO20061122A patent/NO20061122L/no not_active Application Discontinuation
-
2007
- 2007-04-04 CY CY20071100473T patent/CY1106486T1/el unknown
- 2007-12-04 US US11/950,326 patent/US7563895B2/en not_active Expired - Lifetime
-
2008
- 2008-11-03 HR HR20080559T patent/HRP20080559T3/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080559T3 (en) | 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| CY1111671T1 (el) | Ετεροκυκλικη ενωση | |
| ME00443B (me) | Kristalni oblik tercijalne butilaminske soli perindoprila | |
| AR057914A1 (es) | Compuestos organicos de azufre y su uso | |
| RS52313B (en) | MYTHOSIS PROGRESS INHIBITION UNITS | |
| CR8827A (es) | Compuesto heterociclico fusionado | |
| RS52307B (en) | CONDENSED CYCLIC UNITS | |
| ME01992B (fr) | Composes diarylhydantoines | |
| TW200833251A (en) | Pesticidal compositions | |
| AR044695A1 (es) | Derivados de azolidina, utiles como herbicidas. | |
| AR069802A1 (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
| EA200800873A1 (ru) | Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы | |
| ATE387452T1 (de) | Spiroverbindungen mit npy antagonistischer wirkung | |
| CY1113657T1 (el) | Νεα παραγωγα βενζοφαινονης ή αλατα αυτων | |
| RS54175B1 (en) | BROMODOMEN INHIBITORS AND THEIR APPLICATION | |
| CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
| RS52872B (en) | PIRAL UNITS | |
| RS52661B (en) | THERAPEUTIC MEANS | |
| RS52900B (en) | Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them | |
| EA200200819A1 (ru) | Кристаллическая форма ii линезолида | |
| AR054386A1 (es) | Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina | |
| RS51644B (en) | UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES | |
| HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| EA200801365A1 (ru) | Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины |